Investigational drug · Phase 2
SNK01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease, Moderate Alzheimer Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "SNK01"
First trial start
2023
Nov 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SNK01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Moderate Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SNK01" as an intervention, largest first.
NKGen Biotech, Inc.Industry
NCT06189963 · 36 participants (planned) · Start Nov 21, 2023 · Primary completion Mar 2028
Drug: SNK01 · For: Moderate Alzheimer Disease
Sites: Glendale, California; Santa Ana, California; Tarzana, California · 8 sites in all
NKGen Biotech, Inc.Industry
NCT07228078 · 30 participants (planned) · Start Jun 30, 2025 · Primary completion Apr 2028
Drug: SNK01 · For: Alzheimer Disease
Sites: Glendale, California
NKGen Biotech, Inc.Industry
NCT03941262 · 27 participants · Start Jul 15, 2019 · Primary completion Feb 17, 2023
Drug: SNK01; Avelumab and 1 more · For: Refractory Cancer; Metastatic Cancer; Recurrent Cancer and 4 more
Sites: Santa Monica, California
NKMAX Co., Ltd.Industry
NCT04872634 · 24 participants (planned) · Start Jul 8, 2021 · Primary completion May 26, 2023
Drug: SNK01 (Super Natural Killer Cells 01); GC and 1 more · For: Non-small Cell Lung Cancer
Sites: Seoul, South Korea
NKGen Biotech, Inc.Industry
NCT05099549 · 11 participants · Start Nov 3, 2021 · Primary completion Sep 21, 2023
Drug: AFM24; SNK01 · For: Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms and 3 more
Sites: Los Angeles, California; Santa Monica, California; Chicago, Illinois
NKGen Biotech, Inc.Industry
NCT04678453 · 10 participants · Start Jan 6, 2021 · Primary completion Aug 16, 2023
Drug: SNK01 · For: Alzheimer Disease; Neuro-Degenerative Disease
Sites: Tijuana, Mexico
NKGen Biotech, Inc.Industry
NCT03894579 · 9 participants · Start Jul 18, 2019 · Primary completion Dec 3, 2019
Drug: Study Product: SNK01 · For: Plaque Psoriasis
Sites: Tijuana, Mexico
NKGen Biotech, Inc.Industry
NCT04464967 · 0 participants · Start Mar 2021 · Primary completion Aug 2022
Drug: SNK01; Trastuzumab and 1 more · For: Advanced Solid Tumor; Metastatic Cancer; HER2-positive Breast Cancer and 14 more
Newest research
PubMed records naming it or its code names, newest first.
- Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study.
Zúñiga CH, Acosta BI, Menchaca R, et al. · Alzheimers Res Ther 2025
- Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study.
Choi MG, Son GW, Choi MY, et al. · J Immunother Cancer 2024
- A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer.
Kim EJ, Cho YH, Kim DH, et al. · Cancer Res Treat 2022
- Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial.
Park HJ, Kim YM, Jung JS, et al. · Thorac Cancer 2022
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.